This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses against various SARS-CoV-2 variants of concern.
An aqueous dispersion having an aqueous mobile phase and a dispersed phase, wherein the dispersed phase comprises a lipid mixture including a cationically ionisable lipid; and the aqueous mobile phase comprises water; wherein the aqueous dispersion is substantially free of organic solvents, nucleic acids, organic acids, buffers, and inorganic ions, is described. Methods of preparing the aqueous dispersion, nucleic acid-lipid particles and methods of preparing them using the aqueous dispersion, and their use in medicine are disclosed.
The invention provides potency assays for measuring, determining, identifying, quantifying, confirming, and/or validating the therapeutic potential of nucleic acid such as RNA encoding a pharmaceutically active peptide or polypeptide. The potency assays may be performed with nucleic acid such as RNA encoding various types of peptides or polypeptides, including pharmaceutically active peptides or polypeptides comprising one or more antigens or one or more epitopes. Nucleic acid such as RNA having therapeutic potential may be useful in downstream clinical applications, e.g., for eliciting an immune response against one or more antigens or one or more epitopes encoded by the nucleic acid in a subject which immune response may be therapeutic or partially or fully protective. Thus, the nucleic having therapeutic potential may be useful for vaccination.
TRON - Translationale Onkologie an der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz (Germany)
Inventor
Sahin, Ugur
Kreiter, Sebastian
Diken, Mustafa
Vascotto, Fulvia
Salomon, Nadja
Grunwitz, Christian
Abstract
This disclosure relates to the field of therapeutic RNA to treat HPV-positive cancer, in particular anogenital, cervical and penile cancers and cancer in the head and neck region such as cancer in the genital region and head and neck squamous cell carcinoma (HNSCC). Disclosed herein are compositions, uses, and methods for treatment of HPV-positive cancers. Administration of therapeutic RNAs to a patient having HPV-positive cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.
The present invention relates to an antibody-drug conjugate that comprises the antibody trastuzumab for use in a method of treating endometrial cancer. The present invention also relates to the antibody-drug conjugate for use in a method of treating cancer, wherein the method comprises administering the antibody-drug conjugate or pharmaceutically acceptable salt thereof to a patient at a dose in the range of 2.2 mg/kg to 12.0 mg/kg. The present invention also relates to the antibody-drug conjugate for use in a method of treating breast cancer in patients previously treated with an anti-HER2 antibody and/or a taxane. The present invention also relates to compositions comprising the antibody-drug conjugate.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz (Germany)
Inventor
Beissert, Tim
Perkovic, Mario
Gawletta, Stefanie
Sorn, Patrick
Brill, Silke
Nett, Evelin
Abstract
The present invention relates to methods for restoring or improving the ability of a modified nucleotide-containing replicable RNA to be replicated and/or translated. The method includes identifying nucleotide changes in the replicable RNA that compensate for the lowered ability of modified-nucleotide-containing replicable RNA molecules to replicate and/or be translated. The present invention also relates to modified nucleotide-containing replicable RNA molecules incorporating such identified nucleotide changes and the use of such replicable RNA molecules in therapy.
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/67 - General methods for enhancing the expression
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
8.
METHODS FOR PREDICTING THE USEFULNESS OF PROTEINS OR PROTEIN FRAGMENTS FOR IMMUNOTHERAPY
TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG (Germany)
Inventor
Vormehr, Mathias
Sahin, Ugur
Schrörs, Barbara
Löwer, Martin
Boegel, Sebastian
Abstract
The present invention relates to methods for predicting peptides or polypeptides such as T cell epitopes useful for immunotherapy such as for vaccination. In particular, the present invention relates to methods for predicting whether peptides or polypeptides such as tumor-associated antigens or epitopes, in particular tumor-associated neoantigens or neoepitopes, are immunogenic and, in particular, useful for immunotherapy such as for vaccination. The methods of the invention may be used, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.
The present disclosure provides methods for treating an individual with a urothelial carcinoma with an individualized cancer vaccine and a PD-1 axis antagonist.
Tron-Translationale Onkologie An Der Universitatsmedizin Der Johannes (Germany)
Inventor
Perkovic, Mario
Beissert, Tim
Abstract
The present invention relates to a modified nucleotide-containing replicable RNA which is able to be replicated and/or translated at greater levels than those of the corresponding replicable RNA not containing the modified nucleotide(s) and the use of such modified replicable RNA molecules in various types of therapy.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
The present disclosure relates generally to the field of nucleic acid (such as DNA or RNA, in particular mRNA or inhibitory RNA, e.g., siRNA) compositions comprising a multivalent anion (e.g., an inorganic polyphosphate), methods for preparing and storing such compositions, and the use of such compositions in therapy.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
14.
LIPID-BASED FORMULATIONS FOR ADMINISTRATION OF RNA
The present disclosure relates to compositions comprising RNA and a cationically ionizable lipid for delivering RNA to target tissues after administration, in particular after parenteral administration. The present disclosure also relates to methods for delivering RNA to cells of a subject or for treating or preventing a disease or disorder in a subject, wherein the methods comprise administering to a subject a composition of the present disclosure. Furthermore, the present disclosure also relates to methods for delivering a pharmaceutically active peptide or protein to a subject or for treating or preventing a disease or disorder in a subject, wherein the methods comprise administering to a subject an RNA composition of the present disclosure, wherein the RNA encodes the pharmaceutically active peptide or protein.
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENB (Germany)
Inventor
Sahin, Ugur
Haas, Heinrich
Vogel, Annette
Erbar, Stephanie
Walzer, Kerstin
Schlegel, Anne
Hörner, Sebastian
Moreno, Jorge Herrero
Klamp, Thorsten
Kreiter, Sebastian
Diken, Mustafa
Heller, Philipp
Abstract
The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine.
The present invention relates to a method of measuring protein impurities in an RNA composition. In particular, the present invention relates to methods of incubating the RNA composition with a protease of the protease family S8A, such that the protein impurities in the RNA composition are digested to form peptide products. The present invention also relates to methods for reducing protein impurities in an RNA composition and for producing RNA compositions that are suitable for in vivo administration.
The present invention relates to a binding molecule comprising a CFC1 binding domain. The present invention also relates to antibodies comprising the binding molecule.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to mutated polypeptides comprising a fragment crystallisable (Fc) region with reduced affinity for Staphylococcus aureus protein A (SpA). The present disclosure further relates to the treatment of Staphylococcus aureus infections.
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
19.
ANTI-CTLA-4 ANTIBODY FOR TREATMENT OF PATIENTS WITH PROSTATE CANCER AND COMBINATION THERAPY WITH A RADIOLIGAND THERAPEUTIC AGENT
The invention provides an anti-CTLA-4 antibody or a nucleic acid encoding the anti-CTLA-4 antibody for use in treating prostate cancer in a subject, optionally in combination with a radioligand therapeutic agent such as lutetium (177LU) vipivotide tetraxetan. The invention further provides treatment methods for prostate cancer in a subject in need thereof, comprising administering the anti-CTLA-4 antibody or the nucleic acid encoding the anti- CTLA-4 antibody, optionally in combination with a radioligand therapeutic agent such as lutetium (177LU) vipivotide tetraxetan.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
The present invention relates to a binding molecule comprising a CFC1 binding domain. In particular, the present invention relates to a CFC1 binding domain that induces a high rate of internalisation of the binding molecule into a cell expressing CFC1. The present invention further relates to antibodies comprising the binding molecule.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Spain)
Inventor
Metelkina, Olga
Gangluff, Meike
Agrawal, Neha
Schille, Stefan Albrecht
Moreno Herrero, Jorge
Kuriakose Thomas, Alvin
García Fernández, José Manuel
Benito Hernández, Juan Manuel
De La Cruz Ruiz, Noelia
Puerto Madorrán, María José
Abstract
Provided herein are particles and compositions comprising one or more glycolipids and a nucleic acid, wherein the one or more glycolipids are represented by, for example, formula I: G1-G2-G3 or a pharmaceutically acceptable salt thereof.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C07C 335/00 - Thioureas, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups
C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Spain)
Inventor
Metelkina, Olga
Gangluff, Meike
Agrawal, Neha
Albrecht Schille, Stefan
Moreno Herrero, Jorge
Kuriakose Thomas, Alvin
García Fernández, José Manuel
Benito Hernández, Juan Manuel
De La Cruz Ruiz, Noelia
Puerto Madorrán, María José
Abstract
Provided herein are particles and compositions comprising one or more glycolipids and a nucleic acid, wherein the one or more glycolipids are represented by, for example, formula I or a pharmaceutically acceptable salt thereof.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C07C 335/00 - Thioureas, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups
C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
The present invention relates to new pharmaceutical compositions comprising as active ingredient an effective amount of (a) an endolysin comprising the amino acid sequence provided in SEQ ID NO: 1; or (b) an endolysin comprising an amino acid sequence having 80% sequence identity to SEQ ID NO:1, wherein the endolysin has a killing activity against Gardnerella; and at least one pharmaceutically acceptable excipient. Furthermore, the present invention relates to therapeutic uses of said pharmaceutical composition.
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A61K 31/78 - Polymers containing oxygen of acrylic acid or derivatives thereof
Documentation of pharmaceutical operations is typically performed as a combination of paper and electronic records. As a result of good manufacturing practice guidelines, operators constantly move between reading, executing, and documenting. The present disclosure describes a method of handsfree accessing and updating of data during execution of operations, using an extended reality (XR) device. The XR device enables verification of an operator's identity, and connection to a private cloud. A task is initiated by the operator or a third-party user, and the task identifier is sent to the cloud. The cloud retrieves and sends the associated data cluster. The display-only fields of the data cluster are displayed on the screen. The editable fields of the data cluster are presented in specific forms, and the operator uses voice commands to fill in each field. The software sends the updated data cluster to the cloud to replace the original data cluster.
The present invention provides combination therapy using an antibody capable of binding to OX40 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or cancer, or to treat a tumor or cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Disclosed herein are compositions comprising protein antigens and RNA encoding the same (e.g., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can result in an improved immune response as compared to current SARS-COV-2 vaccines.
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
The present invention relates to cyclic peptides useful as epitope tags, and compositions thereof. Furthermore, the invention is directed to methods of their use in complex formation.
ex vivo in vitroin vitro. The present disclosure provides malaria-specific TCRs and nucleic acid encoding the TCRs, methods of making T cells specific for an infectious disease, methods of identifying TCRs, and methods of using the same for determining whether a vaccine induces T cell specific immune response, whether an epitope sequence is presented, and whether an antigen is recognizable by TCRs.
The present invention relates to a co-delivery system comprising one or more nucleic acids encoding a first antibody and a second antibody. In particular, the co-delivery system encodes a first antibody and a second antibody each comprising two antibody chains, and wherein the two antibody chains of each antibody are covalently linked by at least one inter-chain disulphide bond located at a different position in each of the two antibodies. The invention also relates to a vector comprising the co-delivery system, a nucleic acid particle comprising the co-delivery system and a composition comprising the co-delivery system as well as uses of the co-delivery system in a method of therapy and/or a diagnostic method.
The present disclosure relates generally to functionalized particles containing moieties capable of binding Immunoglobulin D (IgD), methods for producing them, and to pharmaceutical compositions containing them and their uses in medicine.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The present invention relates to new therapeutic uses of species-selective phage endolysins, in particular in the treatment of bacterial vaginosis (BV), even more particularly in the treatment of patients suffering from BV who previously failed a treatment with antibiotics, and/or patients suffering from BV wherein the infective bacteria are resistant to a treatment with antibiotics. The present invention also relates to pharmaceutical compositions for uses of the invention and methods of treatment using the same.
The present invention provides an antibody-drug conjugate (ADC), wherein the antibody is conjugated to the drug by cysteine-based site-specific conjugation, wherein the antibody comprises a first polypeptide comprising an immunoglobulin fragment crystallisable (Fc) region, at least one variable domain N-terminal of the Fc region and an engineered IgG hinge region between the Fc region and the at least one variable domain, and wherein the engineered IgG hinge region is heterologous to the Fc region and/or is mutated to provide a predetermined number of cysteine residues.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to antigen binding proteins such as full-length antibodies and fragments and derivatives thereof having the ability to bind to CD3, such as human CD3ε, and nucleic acids encoding such molecules. The present invention also relates to compositions and pharmaceutical compositions comprising said molecules or said nucleic acids or immune effector cells comprising such nucleic acids and to the use thereof in medicine, preferably in the field of immunotherapy for the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
36.
ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING TO CD3 AND THEIR USE IN MEDICINE
The present invention relates to antigen binding proteins such as full-length antibodies and fragments and derivatives thereof having the ability to bind to CD3, such as human CD3ε, and nucleic acids encoding such molecules. In particular, the present invention relates to bispecific antibodies binding to CD3 and a tumor antigen. The present invention also relates to compositions and pharmaceutical compositions comprising said molecules or said nucleic acids or immune effector cells comprising such nucleic acids and to the use thereof in medicine, preferably in the field of immunotherapy for the treatment of cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
37.
MULTISPECIFIC T CELL ENGAGERS COMPOSITIONS AND METHODS OF USE THEREOF
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 15/62 - DNA sequences coding for fusion proteins
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
38.
MULTISPECIFIC T CELL ENGAGERS COMPOSITIONS AND METHODS OF USE THEREOF
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Disclosed herein are RNA polynucleotides comprising a 5′ Cap, a 5′ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and compositions and methods of making and using the same.
The invention relates to agents and methods for targeted delivery of immune effector cells to target cells. In some embodiments, the invention involves providing to a subject immune effector cells genetically modified to express a chimeric antigen receptor (CAR) and a compound (docking compound) comprising a binding moiety for an antigen on target cells and a binding moiety for the CAR. The CAR and the binding moiety for the CAR bind to each other by means of an ALFA-tag and a single-domain antibody binding to the ALFA-tag.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
The present disclosure relates to a tumour necrosis factor receptor 2 (TNFR2) agonist polypeptide comprising (i) a TNFR2 binding domain comprising three TNF homology domains (THD) that specifically bind to TNFR2; and (ii) an Fc domain. The disclosure further relates to a TNFR2 agonist for use in the treatment and/or prevention of - for example - chronic pain or multiple sclerosis.
The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.
The present invention relates to a method for analyzing the structure of 5′ terminus of an RNA molecule in a population of RNA molecules using catalytic nucleic acids, e.g., for determining the presence or absence of a 5′ cap structure.
The present disclosure relates to a nucleic acid molecule for eliciting an antigen-specific CD8+ T-cell response in a subject comprising a coding sequence encoding a polypeptide comprising an N-terminal degron and an antigenic peptide and medical use applications for the nucleic acid molecule of the present disclosure.
The present invention provides nucleic acid compositions and methods of making nucleic acid compositions. Applications of such nucleic acid compositions include uses in therapy.
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of incretin agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides treatment methods using polyribonucleotides encoding incretin agents for various diseases.
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of incretin agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides treatment methods using polyribonucleotides encoding incretin agents for various diseases.
The present invention relates to an antibody-drug conjugate that comprises the antibody trastuzumab for use in a method of treating endometrial cancer. The present invention also relates to the antibody-drug conjugate for use in a method of treating cancer, wherein the method comprises administering the antibody-drug conjugate or pharmaceutically acceptable salt thereof to a patient at a dose in the range of 2.2 mg/kg to 12.0 mg/kg. The present invention also relates to compositions comprising the antibody-drug conjugate.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
50.
METHODS OF TREATMENT USING AGENTS BINDING TO EPCAM AND CD137 IN COMBINATION WITH PD-1 AXIS BINDING ANTAGONISTS
The present disclosure provides for the use of a binding agent that binds to EpCAM and to CD137 in combination with a PD-1 axis binding antagonist in the treatment or prevention of a tumor or cancer, or to prevent progression of a tumor or cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to an antibody-drug conjugate of formula (I) as defined herein, that comprises the antibody trastuzumab, for use in a method of treating endometrial cancer. The present invention also relates to the antibody-drug conjugate for use in a method of treating cancer, wherein the method comprises administering the antibody-drug conjugate or pharmaceutically acceptable salt thereof to a patient at a dose in the range of 2.2 mg/kg to 12.0 mg/kg. The present invention also relates to the antibody-drug conjugate for use in a method of treating breast cancer in patients previously treated with an anti-HER2 antibody and/or a taxane. The present invention also relates to compositions comprising the antibodydrug conjugate.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure provides for the use of a binding agent that binds to EpCAM and to CD137 in combination with a PD-1 axis binding antagonist in the treatment or prevention of a tumor or cancer, or to prevent progression of a tumor or cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
TRON – TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH (Germany)
RESANO GMBH (Germany)
Inventor
Sahin, Ugur
Diken, Mustafa
Krienke, Christina
Leuschner, Florian
Li, Xue
Fischer, Roman
Abstract
Disclosed herein are methods for localized expression of an administered RNA molecule at a site of acute inflammation, methods for treating tissue or organ damage characterized by a site of acute inflammation in the tissue or organ in a subject, methods for treating a subject having a site of acute inflammation in an tissue or organ, methods for treating tissue damage in the heart or brain cause by ischemia in a subject, as well as medical preparations or kits suitable for administration and localized expression at a site of acute inflammation.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The present invention provides improved constructs comprising immunoglobulin-domains. In particular, the present invention provides a novel VHH-CH3 fusion antigen-binding format, as well as improved methods of producing VHH-CH3 fusions.
TRON – TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH (Germany)
RESANO GMBH (Germany)
Inventor
Sahin, Ugur
Diken, Mustafa
Krienke, Christina
Leuschner, Florian
Li, Xue
Fischer, Roman
Abstract
Disclosed herein are methods for localized expression of an administered RNA molecule at a site of acute inflammation, methods for treating tissue or organ damage characterized by a site of acute inflammation in the tissue or organ in a subject, methods for treating a subject having a site of acute inflammation in an tissue or organ, methods for treating tissue damage in the heart or brain cause by ischemia in a subject, as well as medical preparations or kits suitable for administration and localized expression at a site of acute inflammation.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
56.
RNA COMPOSITIONS FOR DELIVERY OF MPOX ANTIGENS AND RELATED METHODS
The present disclosure provides pharmaceutical compositions for delivery of mpox virus antigens (e.g., an mpox vaccine) and related technologies (e.g., components thereof and/or methods relating thereto). For example, the present disclosure provides polyribonucleotides encoding one or more mpox antigens or antigenic fragments thereof.
TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH (Germany)
Inventor
Perkovic, Mario
Beissert, Tim
Nett, Evelin
Yildiz, Aysegül
Zimmermann, Louisa
Erbar, Stephanie
Jacobus, Egon
Krumm, Stefanie
Abstract
Described herein are replicable RNA systems using modified RNA-dependent RNA polymerases that have increased trans-amplifying activity compared to the corresponding unmodified polymerase and their use in methods for treating and preventing diseases.
Consejo Superior de Investigaciones Científicas (CSIC) (Spain)
Universidad de Sevilla (Spain)
Inventor
Moreno Herrero, Jorge
Haas, Heinrich
Erbar, Stephanie
Stahl, Theo Benjamin
García Fernández, José Manuel
Benito Hernández, Juan Manuel
Lopez Fernandez, Jose
Ortiz Mellet, Maria Del Carmen
De La Cruz Ruiz, Noelia
González Cuesta, Manuel
Jacobus Ambuludi, Egon Jack
Vlatkovic, Irena
Abstract
The present disclosure provides complexes comprising: i) a cationic oligosaccharide comprising one or more cationic moieties bonded to a trehalose, a sucrose, or a gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives selected from: a sterol, a helper lipid, an immunomodulator, and a targeting molecule; and uses thereof.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
Consejo Superior de Investigaciones Científicas (CSIC) (Spain)
Inventor
Moreno Herrero, Jorge
Haas, Heinrich
Erbar, Stephanie
García Fernández, José Manuel
Benito Hernández, Juan Manuel
Lopez Fernandez, Jose
Abstract
The present disclosure provides complexes comprising a cationic oligosaccharide and an RNA, wherein the cationic oligosaccharide comprises a plurality of cationic moieties bonded to a trehalose, a sucrose, or a gluco-n-oligosaccharide moiety, where n is 2-6, and a ratio of N/P in the complex is less than 20:1
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
Inventor
Sahin, Ugur
Rooney, Michael Steven
Esaulova, Ekaterina
Zuiani, Adam
Addona, Theresa
Poran, Asaf
Goulding, Scott
Velazquez, Ricardo Sanchez
Uebele, Julia
Güler, Alptekin
Lu, Yu-Jung
Friedman, Harvey
Awasthi, Sita
Cohen, Gary H.
Abstract
The present disclosure provides pharmaceutical compositions for delivery of HSV antigens (e.g., an HSV vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61P 31/22 - Antivirals for DNA viruses for herpes viruses
62.
PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF HERPES SIMPLEX VIRUS ANTIGENS AND RELATED METHODS
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
Inventor
Güler, Alptekin
Velazquez, Ricardo Sanchez
Uebele, Julia
Vogel, Annette
Pfafenrot, Christina
Ernst, Anna Luise
Hein, Stephanie
Hinz, Sabrina
Sahin, Ugur
Rooney, Michael Steven
Esaulova, Ekaterina
Zuiani, Adam
Addona, Theresa
Poran, Asaf
Goulding, Scott
Walls, Alexandra
Srouji, John
Palowitch, Gavin
Dulberger, Charles Lefco
Dany, Sarah Catharina
Strauss, Stefan Thomas
Cohen, Gary H.
Friedman, Harvey
Awasthi, Sita
Weissman, Drew
Hook, Lauren Michelle
Egan, Kevin
Cairns, Tina M.
Atanasiu, Doina
Saw, Wan Ting
Abstract
The present disclosure provides pharmaceutical compositions for delivery of HSV antigens (e.g., an HSV vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).
The invention relates to agents and methods for targeted delivery of nucleic acids to cells. In some embodiments, the invention involves a particle, said particle comprising a connector compound comprising (i) a moiety incorporating the connector compound into the particle through a charge in the moiety incorporating the connector compound into the particle interacting with an opposite charge in the particle, and (ii) a first interacting moiety, and said particle carrying a nucleic acid payload. A docking compound comprising (i) a second interacting moiety, and (ii) a moiety binding to a cell surface antigen interacts with the connector compound through the first interacting moiety and the second interacting moiety binding to each other, and thus targets the complex to a target cell of interest.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
64.
METHOD OF DETERMINING NUCLEIC ACID CONCENTRATION IN AQUEOUS SOLUTION OR DISPERSION
A method of determining the nucleic acid concentration in an aqueous dispersion, the method comprising the steps a) to c): a) providing a sample of the nucleic acid; b) mixing the sample with a medium containing: i) a zwitterionic surfactant; and optionally ii) a mobile phase selected from the group consisting of an alcohol, acetone, and dimethyl sulfoxide, or a mixture of any thereof; and c) measuring the concentration of the nucleic acid using ultraviolet-visible spectroscopy; is provided. A method of determining the nucleic acid concentration in an aqueous solution, the method comprising the steps a) to c): a) providing a sample of the nucleic acid; b) mixing the sample with a medium containing: i) a zwitterionic surfactant; and/or ii) a solvent selected from the group consisting of an alcohol, acetone, and dimethyl sulfoxide, or a mixture of any thereof; and c) measuring the concentration of the nucleic acid using ultraviolet-visible spectroscopy; is also provided.
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
G01N 33/487 - Physical analysis of biological material of liquid biological material
65.
AGENTS AND METHODS FOR TARGETED DELIVERY OF IMMUNE EFFECTOR CELLS
The invention relates to agents and methods for targeted delivery of immune effector cells to target cells. In one embodiment, the invention involves providing to a subject immune effector cells genetically modified to express a chimeric antigen receptor (CAR) and a compound (docking compound) comprising a binding moiety for an antigen on target cells and a further binding moiety for a CAR. The binding moiety for an antigen on target cells and the binding moiety for a CAR are connected through a linking moiety comprising at least one poly-2-(2-(2- aminoethoxy)ethoxy)acetic acid (pAEEA) moiety or a derivative thereof.
The present disclosure provides a compound of formula (I): (I), or a pharmaceutically acceptable salt thereof, that is useful for forming particles (e.g., lipid nanoparticles) for delivery of nucleic acids. The present disclosure further provides particle compositions comprising the compound of formula I, as well as uses thereof.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 295/21 - Radicals derived from sulfur analogues of carbonic acid
C07C 311/32 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
C07C 317/28 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
C07C 323/24 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
C07C 323/25 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C07C 335/08 - Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
C07C 335/40 - Thioureas, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
The invention relates to agents and methods for targeted delivery of payloads to cells. The payload includes a variety of molecules such as therapeutic or diagnostic agents and, in particular, toxins, immunomodulators or radiodiagnostics. In some embodiments, the invention involves providing to a subject a compound comprising a payload moiety and at least two tags (tag conjugate) and a compound binding to the tags of the tag conjugate and a target antigen, e.g., a cell surface antigen on a target cell, (docking compound).
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding a plurality of immunoglobulin chains of anti-HIV antibody agents.
The present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, that is useful for forming particles (e.g., lipid nanoparticles) for delivery of nucleic acids. The present disclosure further provides particle compositions comprising the compound of formula (I), as well as uses thereof.
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07C 323/24 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 295/21 - Radicals derived from sulfur analogues of carbonic acid
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
The disclosure provides RNA therapeutics, e.g. RNA molecules for treating or preventing an infection, and methods for reducing inherent toxicity of antigens or cytotoxicity exhibited by certain microbial antigens or immunogenic variants thereof when expressed intracellularly from RNA, as well as compositions comprising RNA therapeutics produced by such methods. The RNA encoding the antigens, immunogenic variants or fragments thereof is formulated and administered in a way that the antigens, variants or fragments are produced by cells of a subject, in particular after intramuscular or intravenous administration of the RNA and that, at the same time, toxicity or cytotoxicity is avoided.
The invention relates to agents and methods for targeted delivery of nucleic acids to cells. In some embodiments, the invention involves a particle, said particle comprising a connector compound comprising (i) a moiety incorporating the connector compound into the particle through a charge in the moiety incorporating the connector compound into the particle interacting with an opposite charge in the particle, and (ii) a first interacting moiety, and said particle carrying a nucleic acid payload. A docking compound comprising (i) a second interacting moiety, and (ii) a moiety binding to a cell surface antigen interacts with the connector compound through the first interacting moiety and the second interacting moiety binding to each other, and thus targets the complex to a target cell of interest.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
The invention relates to agents and methods for targeted delivery of payloads to cells. The payload includes a variety of molecules such as therapeutic or diagnostic agents and, in particular, toxins, immunomodulators or radiodiagnostics. In some embodiments, the invention involves providing to a subject a compound comprising a payload moiety and a tag (tag conjugate) and a compound binding to the tag of the tag conjugate and a target antigen, e.g., a cell surface antigen on a target cell, (docking compound).
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
74.
RNA COMPOSITIONS ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEIN B ANTIGENS AND USES THEREOF
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
BIONTECH SE (Germany)
Inventor
Friedman, Harvey
Awasthi, Sita
Cohen, Gary H.
Weissman, Drew
Cairns, Tina
Atanasiu, Doina
Saw, Wan Ting
Güler, Alptekin
Strauss, Stefan Thomas
Abstract
The present disclosure provides a polyribonucleotide encoding a polypeptide that comprises a viral antigen from Herpes Simplex Virus-2 (HSV-2); for example, the viral antigen comprises the ectodomain of HSV-2 glycoprotein B. The polyribonucleotide can be formulated as an RNA composition useful for inducing anti-HSV immune responses in a subject.
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
BIONTECH SE (Germany)
Inventor
Friedman, Harvey
Awasthi, Sita
Cohen, Gary H.
Weissman, Drew
Hook, Lauren
Egan, Kevin
Güler, Alptekin
Vogel, Annette
Ernst, Anna Luise
Sanchez Velazquez, Ricardo
Uebele, Julia
Abstract
Disclosed herein are compositions comprising (a) a nucleoside-modified polyribonucleotide encoding a Herpes Simplex Virus-2 (HSV-2) glycoprotein E (gE) antigen or immunogenic fragment thereof, (b) a nucleoside-modified polyribonucleotide encoding an HSV-2 glycoprotein I (gI) antigen or immunogenic fragment thereof, or (c) a combination thereof. Further disclosed are methods for using said compositions for treating an HSV infection.
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of Plasmodium protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides combinations comprising a first pharmaceutical composition comprising a first polyribonucleotide and a second pharmaceutical composition comprising a second polyribonucleotide. In some embodiments, a first polyribonucleotide encodes a first polypeptide that comprises one or more Plasmodium T-cell antigens. In some embodiments, a second polyribonucleotide encodes a second polypeptide that comprises one or more Plasmodium polypeptide (e.g., CSP) or antigenic portions thereof.
TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH (Germany)
Inventor
Gangluff, Meike
Sahin, Ugur
Keil, Isabell Sofia
Diken, Mustafa
Abstract
The invention relates to agents and methods for targeted delivery of RNA such as mRNA encoding a polypeptide comprising a cytokine or a functional variant thereof to immune cells for expression of the polypeptide. Delivering RNA encoding a cytokine to immune cells may be useful for immunomodulation of immune cells, in particular for inducing proliferation of immune cells. In some embodiments, the invention involves a particle, and a targeting compound comprising a moiety incorporating into the particle, e.g., a hydrophobic moiety, and having a binding moiety covalently attached thereto. The particle carries an RNA payload, i.e., RNA encoding a polypeptide comprising a cytokine or a functional variant thereof. Targeting of an immune cell may be achieved by the direct or indirect binding of the targeting compound to cell surface antigens on the target immune cell of interest.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
80.
AGENTS AND METHODS FOR TARGETED DELIVERY OF CYTOKINES TO IMMUNE CELLS
TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH (Germany)
Inventor
Gangluff, Meike
Sahn, Ugur
Keil, Isabell Sofia
Diken, Mustafa
Abstract
The invention relates to agents and methods for targeted delivery of RNA such as mRNA encoding a polypeptide comprising a cytokine ora functional variant thereof to immune cells for expression of the polypeptide. Delivering RNA encoding a cytokine to immune cells may be useful for immunomodulation of immune cells, in particular for inducing proliferation of immune cells. In some embodiments, the invention involves a particle, and a targeting compound comprising a moiety incorporating into the particle, e.g., a hydrophobic moiety, and having a binding moiety covalently attached thereto. The particle carries an RNA payload, i.e., RNA encoding a polypeptide comprising a cytokine or a functional variant thereof. Targeting of an immune cell may be achieved by the direct or indirect binding of the targeting compound to cell surface antigens on the target immune cell of interest.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
The invention provides agents and methods for treating bacterial infections using RNA. The RNA encoding peptidoglycan hydrolases. e.g., endolysins, is formulated and administered in a way that peptidoglycan hydrolase proteins. e.g., endolysin proteins, can be produced and secreted by cells of a subject to combat bacterial infections.
C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
A61K 9/00 - Medicinal preparations characterised by special physical form
The present disclosure relates to chimeric antigen receptor (CAR) expressing immune effector cells showing highly specific and sensitive recognition of CLDN6 expressing cancer cells as well as a high potential for treating cancer in humans.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers, isotopologues, or N-oxides thereof. The present invention is further concerned with inter alia the use of such a compound or salt, stereoisomer, tautomer, isotopologues, or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.
TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG (Germany)
Inventor
Eberle, Florian
Sahin, Ugur
Kuhn, Andreas
Vallazza, Britta
Diken, Mustafa
Abstract
The present invention relates to nucleic acid molecules containing poly(dA:dT) regions which are stabilized in E.coli, methods of propagating such nucleic acid molecules in E.coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly(dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.
The present invention generally relates to binding agents that are at least bispecific for the binding to CD3 and CLDN6, i.e., they are capable of binding to at least CD3 and CLDN6. Specifically, the present invention relates to RNA encoding these binding agents which may be used in the treatment or prevention of cancer in a subject.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
86.
MODULAR MULTIPLATFORM SYSTEM FOR MRNA DRUG PRODUCTION
A drug production facility includes: a first module comprising drug substance and drug product manufacturing equipment including equipment for producing RNA-based drug substance, lipid nanoparticle (LNP)-based drug products and lipoplex-based drug products; and a second module that includes fill and finish process equipment.
Consejo Superior de Investigaciones Científicas (Spain)
Universidad de Sevilla (Spain)
Inventor
Moreno Herrero, Jorge
Haas, Heinrich
Erbar, Stephanie
García Fernández, José Manuel
Ortiz Mellet, Maria Del Carmen
Benito Hernández, Juan Manuel
Lopez Fernandez, Jose
Jimenez Blanco, Jose Luis
Abstract
The present disclosure provides a compound of formula I, as well as complexes and compositions comprising a compound of formula I, wherein said compositions and complexes are useful for delivery of certain agents, including, for example, nucleic acids.
C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07H 1/00 - Processes for the preparation of sugar derivatives
This disclosure relates to the field of RNA to treat lung cancer, in particular non-small-cell lung carcinoma (NSCLC). Lung cancer is the third most frequent malignancy in women and the second most frequent malignancy in men. NSCLC accounts for about 85% of all lung cancers. Disclosed herein are compositions, uses, and methods for treatment of lung cancers. Administration of therapeutic RNAs to a patient having lung cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.
C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07H 1/00 - Processes for the preparation of sugar derivatives
90.
TLR7 AGONIST AND COMBINATIONS FOR CANCER TREATMENT
The present disclosure relates to the specific TLR7 agonist BNT411, such as compositions and kits comprising BNT411, and the use of BNT411 as immunotherapeutic agent in monotherapy and combination therapy to reduce or prevent progression of a tumor, in particular a solid tumor, or treating cancer, in particular a solid cancer.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
91.
MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION WITH ANTI PD-1 ANTIBODIES FOR TREATING CANCERS
The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure relates to RNA particles comprising phospholipids with a phosphatidylserine head group for delivering RNA to target tissues after administration, in particular after parenteral, intratumoral, or peritumoral administration, and compositions comprising such RNA particles. The present disclosure also relates to methods for preparing RNA particles described herein.
The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
This disclosure relates to the field of therapeutic RNA, in particular to treat cancer. Disclosed herein are compositions, uses, and methods for reducing an unwanted response or reaction, or both, in a subject, to RNA encoding an amino acid sequence comprising a cytokine protein.
Disclosed herein are RNA polynucleotides comprising a 5′ Cap, a 5′ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/67 - General methods for enhancing the expression
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
This disclosure relates to the field of preventing or treating virus infection, in particular, the disclosure relates to agents for vaccination against virus infection and inducing effective virus antigen-specific immune responses such as antibody and/or T cell responses and methods for generating and using such agents. Administration of agents such as RNA disclosed herein to a subject can protect the subject against virus infection. Specifically, the present disclosure relates to amino acid sequences comprising at least a portion of a virus protein having amino acid modifications found in other variants of the virus protein. Administration of RNA encoding one or more of the amino acid sequences may provide protection against diverse virus variants. Methods and agents described herein are, in particular, useful for the prevention or treatment of coronavirus infection such as SARS-CoV-2 infection.
The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
98.
ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF
The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
An antibody-drug conjugate (ADC) is provided and comprises an antibody which binds to sialyl Tn (STn) or a glycan terminated by an alpha 2,6-linked sialic acid, conjugated to a drug via a linker, wherein the linker comprises a cleavable linker, and the drug comprises a growth inhibitory agent which is exatecan, deruxtecan, or a derivative thereof. The antibody-drug conjugate (ADC) of the invention comprises a linker cleavable by glucuronidase, for examples the linker comprises a β-glucuronide moiety, such as shown in formula I: Formula (I). The antibody-drug conjugate (ADC) comprises a linker which is linked to, or is modified to link to, the drug via a carbamate linkage, or a linker which is linked to, or is modified to link to, the drug via a quaternary ammonium salt linkage. The antibody-drug conjugate (ADC) may comprise a linker which is PEGylated with a group comprising polyethylene glycol (PEG). Novel linkers for use in ADCs are also described.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
100.
METHOD OF ANALYSING CONTAMINANTS IN RNA PRODUCTS BY ION-PAIR CHROMATOGRAPHY
A method of analysis of substances which are contaminants in a sample comprising target RNA, typically prepared by in vitro transcription, the method comprising the steps of: a) preparing a sample comprising the target RNA; b) separating the target RNA from the substances by liquid chromatography, wherein the liquid chromatography is ion-pair reversed-phase chromatography, wherein the ion pair comprises a primary (C3-8)alkylamine or a salt thereof; and c) analysis of the substances by one or both of: i) ultraviolet-visible spectroscopy and ii) mass spectroscopy is provided.
